日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies

一项 III 期开放标签临床试验,评估每 4 周一次的培尼加糖苷酶 alfa 对既往接受过其他酶替代疗法治疗的法布里病成人患者的疗效。

Holida, Myrl; Linhart, Aleš; Pisani, Antonio; Longo, Nicola; Eyskens, François; Goker-Alpan, Ozlem; Wallace, Eric; Deegan, Patrick; Tøndel, Camilla; Feldt-Rasmussen, Ulla; Hughes, Derralynn; Sakov, Anat; Rocco, Rossana; Almon, Einat Brill; Alon, Sari; Chertkoff, Raul; Warnock, David G; Waldek, Stephen; Wilcox, William R; Bernat, John A

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

在患有法布里病且肾功能恶化的患者中,培尼加糖酶α与阿加糖酶β的头对头试验:来自为期2年的随机III期BALANCE研究的结果

Wallace, Eric L; Goker-Alpan, Ozlem; Wilcox, William R; Holida, Myrl; Bernat, John; Longo, Nicola; Linhart, Aleš; Hughes, Derralynn A; Hopkin, Robert J; Tøndel, Camilla; Langeveld, Mirjam; Giraldo, Pilar; Pisani, Antonio; Germain, Dominique Paul; Mehta, Ankit; Deegan, Patrick B; Molnar, Maria Judit; Ortiz, Damara; Jovanovic, Ana; Muriello, Michael; Barshop, Bruce A; Kimonis, Virginia; Vujkovac, Bojan; Nowak, Albina; Geberhiwot, Tarekegn; Kantola, Ilkka; Knoll, Jasmine; Waldek, Stephen; Nedd, Khan; Karaa, Amel; Brill-Almon, Einat; Alon, Sari; Chertkoff, Raul; Rocco, Rossana; Sakov, Anat; Warnock, David G

Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency

TV-1106(一种用于治疗生长激素缺乏症的长效生长激素治疗药物)的安全性、药代动力学和药效学特性

Cohen-Barak, Orit; Sakov, Anat; Rasamoelisolo, Michele; Bassan, Merav; Brown, Kurt; Mendzelevski, Boaz; Spiegelstein, Ofer

Genotype-environment interactions in mouse behavior: a way out of the problem

基因型与环境在小鼠行为中的相互作用:解决问题的途径

Kafkafi, Neri; Benjamini, Yoav; Sakov, Anat; Elmer, Greg I; Golani, Ilan